PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32097969-5 2020 Although mutations of the regulatory subunit R1alpha of PKA (PRKAR1A) is the main cause of familial and sporadic PPNAD, inactivation of two cAMP-binding phosphodiesterases (PDE11A and PDE8B) are associated with iMAD even if they are also found in PPNAD and PBMAH cases. Cyclic AMP 140-144 phosphodiesterase 11A Homo sapiens 173-179 30941100-3 2019 The cAMP pathway plays an important role in the development and function of endocrine tissues while phosphodiesterases are responsible for ensuring the appropriate intensity of the actions of this pathway by hydrolyzing cAMP to its inactive form 5"-AMP. Cyclic AMP 220-224 phosphodiesterase 11A Homo sapiens 100-118 30941100-8 2019 This unique disturbance of the cAMP-PDE pathway observed in the majority of AIP-mutation positive adenomas could contribute to their well-described poor response to somatostatin analogs and may support a role in tumorigenesis. Cyclic AMP 31-35 phosphodiesterase 11A Homo sapiens 36-39 29594118-5 2018 Benign adrenal cortical tumors presenting with Cushing syndrome often have diverse mutations (PRKACA, PRKAR1A, GNAS, PDE11A, and PDE8B) involving the cyclic AMP signaling pathway. Cyclic AMP 150-160 phosphodiesterase 11A Homo sapiens 117-123 25578602-1 2015 The concentration of the important second messenger cAMP is regulated by phosphodiesterases (PDEs) and hence an attractive drug target. Cyclic AMP 52-56 phosphodiesterase 11A Homo sapiens 73-91 30075949-5 2018 Lately, ARMC5 was linked to the cyclic AMP signaling pathway, which could be implicated in all of mechanisms of cortisol-secreting by macronodules adrenal hyperplasia and the molecular defects in: G protein aberrant receptors; MC2R; GNAS; PRKAR1A; PDE11A; PDE8B. Cyclic AMP 32-42 phosphodiesterase 11A Homo sapiens 248-254 26724956-6 2017 Interestingly, cAMP-PDE activity was 18 times higher in the DRMs than in the Triton-soluble fraction of cell membranes and was 7.7 times higher in the cytosol than in the DRMs. Cyclic AMP 15-19 phosphodiesterase 11A Homo sapiens 20-23 26724956-7 2017 cAMP-PDE activity in mural granulosa cells was mainly contributed by the PDE8 and PDE11 families. Cyclic AMP 0-4 phosphodiesterase 11A Homo sapiens 5-8 26724956-9 2017 In the cell membrane, the cAMP-PDE activity is mainly contributed by the DRMs. Cyclic AMP 26-30 phosphodiesterase 11A Homo sapiens 31-34 27625633-2 2016 Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Cyclic AMP 88-118 phosphodiesterase 11A Homo sapiens 0-18 27625633-2 2016 Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Cyclic AMP 88-118 phosphodiesterase 11A Homo sapiens 20-24 27625633-2 2016 Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Cyclic AMP 120-124 phosphodiesterase 11A Homo sapiens 0-18 27625633-2 2016 Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including cyclic adenosine monophosphate (cAMP). Cyclic AMP 120-124 phosphodiesterase 11A Homo sapiens 20-24 27625633-3 2016 Inactivating mutations and other functional variants in PDE11A and PDE8B, two cAMP-binding PDEs, predispose to ACTs. Cyclic AMP 78-82 phosphodiesterase 11A Homo sapiens 56-62 27625633-7 2016 PDEs confer an increased risk of ACT formation probably through, primarily, their action on cAMP levels, but other actions might be possible. Cyclic AMP 92-96 phosphodiesterase 11A Homo sapiens 0-4 28956334-2 2017 PDE11A is a dual-specific PDE, breaking down both cAMP and cGMP. Cyclic AMP 50-54 phosphodiesterase 11A Homo sapiens 0-3 25578602-1 2015 The concentration of the important second messenger cAMP is regulated by phosphodiesterases (PDEs) and hence an attractive drug target. Cyclic AMP 52-56 phosphodiesterase 11A Homo sapiens 93-97 23771924-2 2013 We reported inactivating germline mutations of the cAMP-binding phosphodiesterase 11A (PDE11A) as modifiers of FTGCT risk. Cyclic AMP 51-55 phosphodiesterase 11A Homo sapiens 87-93 25232906-2 2014 Phosphodiesterases (PDEs) are key regulatory enzymes of intracellular cAMP/cGMP levels. Cyclic AMP 70-74 phosphodiesterase 11A Homo sapiens 0-18 25056711-1 2015 By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. Cyclic AMP 28-58 phosphodiesterase 11A Homo sapiens 127-145 25056711-1 2015 By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), cyclic nucleotide phosphodiesterases are critical regulators of their intracellular concentrations and their biological effects. Cyclic AMP 60-64 phosphodiesterase 11A Homo sapiens 127-145 25232906-2 2014 Phosphodiesterases (PDEs) are key regulatory enzymes of intracellular cAMP/cGMP levels. Cyclic AMP 70-74 phosphodiesterase 11A Homo sapiens 20-24 22996146-1 2012 CONTEXT: Phosphodiesterases (PDEs) are key regulatory enzymes of intracellular cAMP levels. Cyclic AMP 79-83 phosphodiesterase 11A Homo sapiens 9-27 22996146-1 2012 CONTEXT: Phosphodiesterases (PDEs) are key regulatory enzymes of intracellular cAMP levels. Cyclic AMP 79-83 phosphodiesterase 11A Homo sapiens 29-33 22996146-7 2012 Transfection of the two PDE11A variants found in AIMAH patients only (D609N or M878V) showed that cAMP levels were higher, after forskolin stimulation, in cells transfected with the PDE11A mutants, compared to cells transfected with the wild-type PDE11A in HEK 293 cells (P < 0.05). Cyclic AMP 98-102 phosphodiesterase 11A Homo sapiens 24-30 22996146-7 2012 Transfection of the two PDE11A variants found in AIMAH patients only (D609N or M878V) showed that cAMP levels were higher, after forskolin stimulation, in cells transfected with the PDE11A mutants, compared to cells transfected with the wild-type PDE11A in HEK 293 cells (P < 0.05). Cyclic AMP 98-102 phosphodiesterase 11A Homo sapiens 182-188 22996146-7 2012 Transfection of the two PDE11A variants found in AIMAH patients only (D609N or M878V) showed that cAMP levels were higher, after forskolin stimulation, in cells transfected with the PDE11A mutants, compared to cells transfected with the wild-type PDE11A in HEK 293 cells (P < 0.05). Cyclic AMP 98-102 phosphodiesterase 11A Homo sapiens 182-188 22996146-8 2012 Moreover, transfection with mutants PDE11A increased transcriptional activity of a cAMP-response element reporter construct compared to wild-type PDE11A in HEK 293 cells (P < 0.0004 for D609N and P < 0.003 for M878V) and in the adrenocortical H295R cells (P < 0.05 for D609N and M878V). Cyclic AMP 83-87 phosphodiesterase 11A Homo sapiens 36-42 22996146-9 2012 In addition, analysis of cAMP levels in intact living culture cells by fluorescence resonance energy transfer probes showed increased cAMP in forskolin-treated cells transfected with PDE11A variants compared with wild-type PDE11A (P < 0.05). Cyclic AMP 25-29 phosphodiesterase 11A Homo sapiens 183-189 22996146-9 2012 In addition, analysis of cAMP levels in intact living culture cells by fluorescence resonance energy transfer probes showed increased cAMP in forskolin-treated cells transfected with PDE11A variants compared with wild-type PDE11A (P < 0.05). Cyclic AMP 134-138 phosphodiesterase 11A Homo sapiens 183-189 19429701-11 2009 CONCLUSION: Lesions of the adrenal associated with AICS, independently of their GNAS, PRKAR1A, PDE11A, and PDE8B mutation status, have functional abnormalities of cAMP signaling. Cyclic AMP 163-167 phosphodiesterase 11A Homo sapiens 95-101 21047926-10 2011 The simultaneous inactivation of PRKAR1A and PDE11A by small inhibitory RNA led to an increase in cAMP-regulatory element-mediated transcriptional activity under basal conditions and after stimulation by forskolin. Cyclic AMP 98-102 phosphodiesterase 11A Homo sapiens 45-51 19689430-5 2009 PDE10A and PDE11A are the two most recently described PDEs and it has been suggested that their GAF domains bind to cAMP and cGMP respectively. Cyclic AMP 116-120 phosphodiesterase 11A Homo sapiens 11-17 11121118-2 2001 PDE11A is a dual-substrate, cAMP and cGMP, cyclic nucleotide phosphodiesterase (PDE). Cyclic AMP 28-32 phosphodiesterase 11A Homo sapiens 0-6 17696499-1 2007 The phosphodiesterase-11A (PDE11) family consists of four splice variants (PDE11A1-PDE11A4) that contain a conserved carboxyl-terminal (C-terminal) catalytic domain that hydrolyzes cAMP and cGMP; the amino-termini (N-termini) vary in length and amino acid sequence. Cyclic AMP 181-185 phosphodiesterase 11A Homo sapiens 4-25 17696499-1 2007 The phosphodiesterase-11A (PDE11) family consists of four splice variants (PDE11A1-PDE11A4) that contain a conserved carboxyl-terminal (C-terminal) catalytic domain that hydrolyzes cAMP and cGMP; the amino-termini (N-termini) vary in length and amino acid sequence. Cyclic AMP 181-185 phosphodiesterase 11A Homo sapiens 27-32 17036196-12 2006 Interestingly, both PRKAR1A and PDE11A gene products control the cAMP signaling pathway, which can be altered at various levels in endocrine tumors. Cyclic AMP 65-69 phosphodiesterase 11A Homo sapiens 32-38 15995148-10 2005 Our results suggest that PDE11A might be involved in multiple physiological processes in various organs via its ability to modulate intracellular cAMP and cGMP levels. Cyclic AMP 146-150 phosphodiesterase 11A Homo sapiens 25-31 19557111-1 2009 Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the intracellular second messengers cAMP and cGMP to their corresponding monophosphates. Cyclic AMP 90-94 phosphodiesterase 11A Homo sapiens 38-42 18431404-3 2008 A genome-wide association study identified inactivating phosphodiesterase (PDE) 11A (PDE11A)-sequencing defects as low-penetrance predisposing factors for iMAD and related abnormalities; we also described a mutation (c.914A > C/H305P) in cyclic AMP (cAMP)-specific PDE8B, in a patient with iMAD. Cyclic AMP 241-251 phosphodiesterase 11A Homo sapiens 75-83 18431404-3 2008 A genome-wide association study identified inactivating phosphodiesterase (PDE) 11A (PDE11A)-sequencing defects as low-penetrance predisposing factors for iMAD and related abnormalities; we also described a mutation (c.914A > C/H305P) in cyclic AMP (cAMP)-specific PDE8B, in a patient with iMAD. Cyclic AMP 241-251 phosphodiesterase 11A Homo sapiens 85-91 18431404-3 2008 A genome-wide association study identified inactivating phosphodiesterase (PDE) 11A (PDE11A)-sequencing defects as low-penetrance predisposing factors for iMAD and related abnormalities; we also described a mutation (c.914A > C/H305P) in cyclic AMP (cAMP)-specific PDE8B, in a patient with iMAD. Cyclic AMP 253-257 phosphodiesterase 11A Homo sapiens 75-83 18431404-3 2008 A genome-wide association study identified inactivating phosphodiesterase (PDE) 11A (PDE11A)-sequencing defects as low-penetrance predisposing factors for iMAD and related abnormalities; we also described a mutation (c.914A > C/H305P) in cyclic AMP (cAMP)-specific PDE8B, in a patient with iMAD. Cyclic AMP 253-257 phosphodiesterase 11A Homo sapiens 85-91 18438169-2 2008 It focuses on the role of genetic defects in cyclic-AMP (cAMP) signaling-related molecules, namely PRKAR1A, GNAS, PDE11A, and PDE8B in the predisposition to tumor formation. Cyclic AMP 45-55 phosphodiesterase 11A Homo sapiens 114-120 18438169-2 2008 It focuses on the role of genetic defects in cyclic-AMP (cAMP) signaling-related molecules, namely PRKAR1A, GNAS, PDE11A, and PDE8B in the predisposition to tumor formation. Cyclic AMP 57-61 phosphodiesterase 11A Homo sapiens 114-120 16767104-8 2006 PDE11A codes for a dual-specificity PDE that is expressed in adrenal cortex and is partially inhibited by tadalafil and other PDE inhibitors; its germline inactivation is associated with adrenocortical hyperplasia, suggesting another means by which dysregulation of cAMP signaling causes endocrine tumors. Cyclic AMP 266-270 phosphodiesterase 11A Homo sapiens 0-6 16767104-8 2006 PDE11A codes for a dual-specificity PDE that is expressed in adrenal cortex and is partially inhibited by tadalafil and other PDE inhibitors; its germline inactivation is associated with adrenocortical hyperplasia, suggesting another means by which dysregulation of cAMP signaling causes endocrine tumors. Cyclic AMP 266-270 phosphodiesterase 11A Homo sapiens 0-3 16767104-8 2006 PDE11A codes for a dual-specificity PDE that is expressed in adrenal cortex and is partially inhibited by tadalafil and other PDE inhibitors; its germline inactivation is associated with adrenocortical hyperplasia, suggesting another means by which dysregulation of cAMP signaling causes endocrine tumors. Cyclic AMP 266-270 phosphodiesterase 11A Homo sapiens 36-39 15627479-10 2005 Expression of the following cAMP-PDE subtypes were detected by reverse transcriptase PCR (RT-PCR): PDE1A, PDE1C, PDE2A, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE7A, PDE7B, PDE8A, PDE10A and PDE11A. Cyclic AMP 28-32 phosphodiesterase 11A Homo sapiens 187-193 11050148-1 2000 Phosphodiesterase 11A (PDE11A) is a recently identified family of cAMP and cGMP hydrolyzing enzymes. Cyclic AMP 66-70 phosphodiesterase 11A Homo sapiens 0-21 11050148-1 2000 Phosphodiesterase 11A (PDE11A) is a recently identified family of cAMP and cGMP hydrolyzing enzymes. Cyclic AMP 66-70 phosphodiesterase 11A Homo sapiens 23-29 11050148-15 2000 Both PDEs showed a V(max) ratio for cAMP/cGMP of approximately 1.0. Cyclic AMP 36-40 phosphodiesterase 11A Homo sapiens 5-9 10725373-9 2000 Therefore, PDE11A represents a dual-substrate PDE that may regulate both cGMP and cAMP under physiological conditions. Cyclic AMP 82-86 phosphodiesterase 11A Homo sapiens 11-17 35402764-3 2022 Different molecular mechanisms involving the actors of the cAMP/protein kinase A pathway have been implicated in the development of PMAH, including germline and/or somatic molecular defects such as hyperexpression of the G-protein aberrant receptors and pathogenic variants of MC2R, GNAS, PRKAR1A, and PDE11A. Cyclic AMP 59-63 phosphodiesterase 11A Homo sapiens 302-308 33835157-7 2021 PDE11A variants or PDE11A shRNA also caused increased cAMP levels, protein kinase A (PKA) activation, and cAMP response element-binding protein (CREB) phosphorylation. Cyclic AMP 54-58 phosphodiesterase 11A Homo sapiens 0-6 33835157-7 2021 PDE11A variants or PDE11A shRNA also caused increased cAMP levels, protein kinase A (PKA) activation, and cAMP response element-binding protein (CREB) phosphorylation. Cyclic AMP 54-58 phosphodiesterase 11A Homo sapiens 19-25 33127481-1 2021 Phosphodiesterases catalyze the hydrolysis of cyclic nucleotides and maintain physiologic levels of intracellular concentrations of cyclic adenosine and guanosine mono-phosphate (cAMP and cGMP, respectively). Cyclic AMP 179-183 phosphodiesterase 11A Homo sapiens 0-18